Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96RQ9
UPID:
OXLA_HUMAN
Alternative names:
Interleukin-4-induced protein 1; Protein Fig-1
Alternative UPACC:
Q96RQ9; Q1WMJ3; Q4GZN1; Q4GZN2; Q6P2Q3; Q8TEM5; Q96RQ8
Background:
L-amino-acid oxidase, known as Interleukin-4-induced protein 1 or Protein Fig-1, plays a pivotal role in immunoregulation. It preferentially metabolizes L-aromatic amino acids into specific acids, exhibiting weak L-arginine oxidase activity. This protein is instrumental in Trp degradation, leading to AHR activation, which influences immunity and cancer progression by affecting cancer cell motility and adaptive immunity suppression.
Therapeutic significance:
Understanding the role of L-amino-acid oxidase could open doors to potential therapeutic strategies. Its involvement in Trp degradation and AHR activation presents a unique target for modulating immune responses and cancer progression.